The results in Figure 3 are certainly promising. Has anyone been able to find the mentioned supplementary material though? > A post-hoc exploratory analysis of

The results in Figure 3 are certainly promising. Has anyone been able to find the mentioned supplementary material though? > A post-hoc exploratory analysis of immunogenicity in subgroups of participants aged ≥55-<65, ≥65-74 and ≥75 years was performed (Tables S6 and S7). Increases in levels of anti-SARS-CoV-2-spike bAb and nAb at days 29 and post-second vaccination at both the 50 and 100 ug doses were generally comparable across the age subgroups and with those observed in the younger (18-55 years) study participants. Seroconversion rates were also comparable across the age groups and with those in the younger participants. It should be noted that the small size of the ≥75 year-old subgroup (n=22) precludes definitive conclusions to be made. There doesn't seem to be any link to supplementary material at either the Elsevier page [1] nor the NIH page [2]. The clinical trial registration [3] suggests that there was an update just a few days ago, so perhaps they're just waiting to upload a new PDF? [1] https://www.sciencedirect.com/science/article/pii/S0264410X21001535 https://www.sciencedirect.com/science/article/pii/S0264410X2... [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871769/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871769/ [3] https://clinicaltrials.gov/ct2/show/study/NCT04405076 https://clinicaltrials.gov/ct2/show/study/NCT04405076